Crane Rosemary A 4

What Happened

• Rosemary A. Crane, a director of Teva Pharmaceutical Industries Ltd. (TEVA), received a grant of 7,242 restricted share units (RSUs) on May 28, 2026. The award is recorded as a derivative acquisition at $0.00 (no cash paid). The RSUs are contingent rights that may be settled for ordinary shares or, at the committee’s option, cash.

Key Details

• Transaction date: May 28, 2026; Form 4 filed June 1, 2026 (timely filing).
• Security: 7,242 restricted share units (derivative securities), transaction code A (award/grant).
• Price: $0.00 per RSU (grant).
• Vesting: RSUs vest on May 28, 2027 (one-year vesting, per footnote).
• Settlement: Each RSU represents a contingent right to one ordinary share or the cash value of one ordinary share (committee option).
• ADR note: Ordinary shares may be represented by American Depositary Shares (each currently represents one ordinary share).
• Shares owned after the grant: not specified in the provided filing.

Context

• RSU grants are common forms of equity compensation for executives and directors and do not represent an immediate purchase of shares; they vest in the future and may be settled in stock or cash. Such awards are routine compensation and should not be interpreted alone as a buy/sell signal.